Denali Therapeutics (DNLI) vs Tarsus Pharmaceuticals (TARS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Denali Therapeutics (DNLI) has outperformed Tarsus Pharmaceuticals (TARS) over the past year, gaining 28.6% versus a gain of 7.6%. Over five years, TARS leads with a +158.1% price change compared with -57.9% for DNLI. Tarsus Pharmaceuticals is the larger company by market cap ($3.44 billion vs $3.06 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | TARS |
|---|---|---|
| Share price | $19.16 | $73.61 |
| Market cap | $3.06B | $3.44B |
| 1-day change | -0.62% | -0.67% |
| YTD return | +16.05% | -10.10% |
| 1-year return | +28.59% | +7.59% |
| 5-year return | -57.95% | +158.10% |
| EPS (TTM) | $-2.82 | $-1.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.30 | $91.53 |
| 52-week low | $13.75 | $53.89 |
| Distance from 52-week high | -29.82% | -19.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.20% | +35.17% |
| Average volume | 1.61M | 906.66K |
| Shares outstanding | 159.85M | 46.79M |
| Employees | 503 | 370 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNLI has outperformed TARS by 21.0 percentage points over the past year.
- The two companies sit in different sectors: Denali Therapeutics in Healthcare and Tarsus Pharmaceuticals in Health Care.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Healthcare · Biotechnology · 503 employees
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
DNLI vs TARS FAQ
Which is bigger, Denali Therapeutics or Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals (TARS) is larger, with a market capitalization of $3.44B compared with $3.06B for Denali Therapeutics (DNLI).
Which stock has performed better over the past year, DNLI or TARS?
DNLI returned +28.59% over the past 12 months, compared with +7.59% for TARS (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and Tarsus Pharmaceuticals in the same industry?
No. Denali Therapeutics is in the Healthcare sector, while Tarsus Pharmaceuticals is in Health Care.